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OlaparibOlaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase
(PARP) inhibitor currently under investigation in patients with solid tumors. To study the clinical potential of
olaparib as a single-agent for the treatment of acute myeloid leukemia (AML) patients, we analyzed the
in vitro sensitivity of AML cell lines and primary blasts. Clinically achievable concentrations of olaparib were
able to induce cell death in the majority of primary AML case samples (88%) and tested cell lines. At these con-
centrations, olaparib preferentially killed leukemic blasts sparing normal lymphocytes derived from the samepa-
tient and did not substantially affect the viability of normal bone marrow and CD34-enriched peripheral blood
cells obtained from healthy donors. Most primary AML analyzed were characterized by low BRCA1 mRNA level
and undetectable protein expression that likely contributed to explain their sensitivity to olaparib. Noteworthy,
while PARP1 over-expression was detected in blasts not responsive to olaparib, phosphorylation of the histone
H2AFX (γH2AX)was associatedwith drug sensitivity. As to genetic features of tested cases the highest sensitivity
was shown by a patient carrying a 11q23 deletion. The high sensitivity of AML blasts and the identiﬁcation of
biomarkers potentially able to predict response and/or resistance may foster further investigation of olaparib
monotherapy for AML patients unﬁt to conventional chemotherapy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease which
comprises distinct subtypes deﬁned by speciﬁc morphological, cytoge-
netic, molecular and gene expression characteristics [1]. Modern AML
classiﬁcation ismainly based on chromosome abnormalities (insertions,
deletions and translocations) and other recurrent genetic changes inserine/threonine kinase; ATM, ATM serine/threonine kinase, (ataxia telangiectasiamutated); BM, bonemarrow; BRCA1, breast
SA, bovine serumalbumin; CD45, protein tyrosine phosphatase receptor type C;DAPI, 4,6 diamidino-2-phenylindole; DMSO, di-
cytometry;FLT3,fms-relatedtyrosinekinase3;FLT3-ITD,FLT3internaltandemduplications;FLT3LG,fms-relatedtyrosinekinase
nase;H2AFX,H2Ahistone family,memberX;γH2AX,Ser139phosphorylatedH2AFX;HR,homologousrecombination; IC50, inhib-
olog1;MMR,mismatchrepair system;MRE11A,MRE11meiotic recombination11homologA(S. cerevisiae);MSH2,mutShomo-
TS, 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; NAD, nicotinamide
phosphoproteinB23,numatrin);NPM1mutA,NPM1mutationtypeA;PAR,poly(ADP-ribose); PARP1,poly(ADP-ribose)polymer-
inhibitors; PARylation,poly(ADP-ribosyl)ation;PB,peripheralblood;PI, propidiumiodide; qRT-PCR, real-timepolymerase chain
r, (KIT ligand); SSB, single strand breaks
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aspeciﬁc genes such as nucleophosmin (NPM1) and fms-related tyrosine
kinase 3 (FLT3). The analysis of these alterations allows the identiﬁcation
at diagnosis of prognostically discrete subtypes of AML which in turn
may enable the adoption of risk-adapted therapeutic strategies [2].
Despite important advances in the understanding of the molecular
basis of AML, survival outcomes have not signiﬁcantly improved over
the past 20 years, indicating the need of more effective and less toxic
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ic abnormalities of AML blasts and their altered signaling pathways
appear to be promising approaches. In this regard, the inhibitors of
poly(ADP-ribose) polymerase (PARP) are attractive candidates for
AML treatment.
The PARP family comprises a number of enzymes that transfer ADP-
ribose to acceptor proteins using NAD+as substrate resulting inmono-
or poly(ADP-ribosyl)ation (PARylation) of proteins [3]. Among the
proteins capable of synthesizing ADP-ribose polymers (PAR), PARP1 is
responsible formost of the total cellular PARylation activity [4]. Through
PARylation, PARP1 controls a wide array of cellular processes, such as
DNA repair, gene transcription, cell division and death. The rationale
for using PARP inhibitors (PARPi) as single agents, as previously sug-
gested by Ashworth's and Helleday's groups [5,6], relies on their ability
to selectively kill BRCA1 or BRCA2 mutated breast or ovarian cancers
with a defective repair of DNA double strand breaks (DSB) by homolo-
gous recombination (HR) [7]. In the presence of PARPi, single strand
breaks (SSB) that are continuously generated by endogenous oxidants
or by replication errors, are no longer repaired by the base excision
repair (in which PARP1 and PARP2 play a role) and are converted into
DSB upon collision with the replication fork. Normal cells will repair
DSB by HR and survive, whereas HR-deﬁcient tumor cells will not repair
DSB and die or, alternatively, attempt to repair DSB activating the error-
prone non-homologous end-joining pathway that causes genomic
instability and eventual lethality [8]. Thus, the concomitant inhibition
of PARP activity and the lack of function of HR are synthetic lethal
conditions.
Besidesmutations, lowexpression of BRCA1/2 and lack of function of
other proteins involved in HR pathway or in DSB sensing may cause
HR-deﬁciency and confer tumor cells a “BRCAness” phenotype [9,10].
For instance, cells with defective ataxia telangiectasia mutated (ATM)
protein, a kinase quickly activated after the induction of DSB [11], are
more sensitive to PARPi than ATM-proﬁcient cells [12–15]. Moreover,
aberrations of the MRE11A–RAD50–NBS1 complex, essential in DNA
damage detection [12,16–18], silencing or deletion of ATR, RAD51 and
Fanconi anemia proteins, which are required for an efﬁcient HR [12,
19,20], reduced expression of mismatch repair components MSH2,
MSH6 and MLH1, causing genomic instability [18], all represent condi-
tions that may sensitize cancer cells to PARPi monotherapy.
Recent studies performed in leukemia cell lines and primary
myelodysplastic syndromes or AMLs have shown that PARPi might
be a suitable therapeutic strategy [21], especially for a subset of my-
eloid malignancies with microsatellite instability [18]. Among the
different PARPi currently under investigation, olaparib (AZD-2281,
Ku-0059436) is a well-tolerated and potent PARP1 and PARP2 inhibi-
tor which has shown promising results in clinical trials for solid tumors
[22–27]. Presently, olaparib as monotherapy (300 mg twice daily) has
reached the phase III development as maintenance treatment for
BRCA mutated ovarian cancer after chemotherapy with platinum
agents (clinicaltrials.gov).
In the present study we investigated the in vitro sensitivity to
olaparib of AML cell lines and primary patient blasts and found that ex-
posure to a single clinically relevant concentration of the PARPi exerted
anti-proliferative and apoptotic effects in the majority of cases (88%).
Moreover, we found that BRCA1 proﬁciency and PARP1 over-
expression designated AML blasts not responsive to olaparib. Finally,
the sensitivity of AML cells to the PARPi directly correlated with phos-
phorylation of the histone H2AFX on Ser139 (γH2AX), which is
regarded as an indicator of DSB [28].
2. Materials and methods
2.1. Primary AML blasts, cell lines and culture conditions
Freshly isolated primary blasts were obtained from bone marrow
(BM) aspirates of adult patients with newly diagnosed AML beforestarting chemotherapy. The ﬁrst 14 patients were numbered in order
of arrival and selected for a blast inﬁltration≥ 60% in the BM at disease
presentation. Three patients were selected for blast percentages ≤ 40%
to study the inﬂuence of olaparib in matched myeloblats and normal
cells; in these latter cases, however, it was not possible to recover
enough blasts for immunoblot analyses. Eight additional AML samples
(with ≥60% blasts) were analyzed only for mRNA expression experi-
ments. All patients provided written informed consent according to
institutional guidelines and the study was approved by the IRB at
“Policlinico Tor Vergata”.
Mononuclear cells from the BMof 25 patients and 10 healthy donors
were isolated by Lympholyte-H (Cedarlane) according to the
manufacturer's instructions. Two CD34-enriched cells were obtained
after G-CSF-mobilization from the peripheral blood of healthy donors
and after Lympholyte-H separation.
Since freshly isolated AML cells are typically arrested at G0/G1
phase, cells were exposed to 3 different mitogenic stimuli and cultured
for 3 days before starting chemosensitivity assays. Brieﬂy, 106 primary
AML cells/ml were seeded into a culture ﬂask in complete RPMI medi-
um (Sigma-Aldrich) [with 2 mM L-glutamine (EuroClone) and 1% peni-
cillin/streptomycin (EuroClone)] supplemented with 20% fetal bovine
serum (FBS) (PAA Laboratories), 10 ng/ml each of IL-3, SCF and
FLT3LG (Peprotech).
The HL-60, U937, NB4 (American Type Culture Collection) and HL-
60R (kindly donated by Richard Darley, University of Wales, Cardiff,
UK) leukemia cell lineswere cultured in completemedium supplement-
ed with 10% FBS, whereas OCI-AML2 and OCI-AML3 (DSMZ-German
Collection) leukemia cell lines were cultured in the presence of 20% FBS.
2.2. Drug treatment and survival assay
The stock solution of olaparib (Selleck Cehmicals) was prepared by
dissolving 10 mg of the drug in 200 μl of dimethylsulfoxide (DMSO)
(Sigma) and then diluted with RPMI to the concentration of 2 mM.
The aliquots were stored at−80 °C. For each experiment a new aliquot
was thawed and used.
For survival assay stimulated primary AML cells were collected, cen-
trifuged, suspended in fresh completemedium (time0 on the graphics),
and seeded at 106 cells/ml in duplicate for each point in 24-well culture
plates. Olaparib was added at the beginning of each experiment and left
in the culturemediumduring the entire period of incubation. Cells were
counted by trypan blue dye exclusion in quadruplicate and the surviv-
ing fraction was calculated with respect to the untreated control. Since
in vitro culture of primary AML blasts could be achieved for 7–14 days
only, depending on the AML sample, we performed the assays at up to
7 days after drug exposure. Experiments with normal cells were per-
formed with the same procedure.
For the analysis of survival of AML lines, cells were plated in 96-well
plates at 104 or 103 cells/ml, exposed to graded concentrations of
olaparib and cultured for 3 or 7 days, respectively. Cell survival was
evaluated by the Kit CellTiter 96® AQueous One Solution Cell Prolifera-
tion Assay (Promega), according to the manufacturer's instructions. At
the end of each experiment the absorbance of metabolized MTS was
read at 490 nm using a Victor X Plate Reader (PerkinElmer).
The olaparib inhibitory concentration 50 (IC50), deﬁned as the drug
concentration capable of inhibiting 50% of cell growth compared to
untreated control, was calculated with the GraphPad Prism 5 software
by using linear regression. Statistical correlations with IC50 were per-
formed using non-parametric one-tailed Spearman's tests. Results
were considered signiﬁcant for p values ≤ 0.05.
2.3. Flow cytometry and apoptotic assays
Apoptosis in primary AML samples was assayed using an annexin V
apoptosis kit (GFP Certiﬁed™ Apoptosis/Necrosis Detection Kit, Enzo
Life Sciences), according to the manufacturer's instructions, and
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Fig. 1. Primary AML cells are killed in vitro by olaparib. Primary AML cells were cultured with IL-3, SCF and FLT3LG for 3 days and then treated (time 0) with increasing concentrations of
olaparib. Cell proliferationwas evaluated by count of viable cells using trypan blue exclusion at 3, 5 and 7 days. Standard error (SE) of replicate countswas±10% andwas not indicated in
theﬁgure. AML sampleswere divided in two different groups on the basis of their proliferation rate. The IC50s of olaparib were calculated after 7 days of exposure. (A) Growth curves of 11
proliferating primary AML cells untreated (left panel) and the surviving fractions after 7 days of treatmentwith olaparib (right panel). (B) Growth curves of 3 not proliferating primary AML
cells untreated (left panel) and the surviving fractions after 7 days of treatment with olaparib (right panel). (C) Apoptosis induction by olaparib in primary AML cells, following 7 days of
exposure to increasing concentrations of olaparib. The percentages of cells treated with olaparib undergoing early and late apoptosis, as detected by Annexin V/PI by FACS analysis, are
indicated after subtraction of apoptosis in the untreated controls. In the ﬁgure AML samples were arranged from the most resistant to the most sensitive. (D) Representative plot of
Annexin V/PI analysis of the AML-5 sample. Necrotic cells (i.e., PI positive and Annexin V negative) were shown in the bottom right quadrant and were b1% in all analyzed AML samples.
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AML blasts, 5 × 105 cells, untreated or treated with 10 μM olaparib for 7
days, were stainedwith anti-human CD45 APC-eFluor780 (e-Bioscience),
washed with PBS and assayed for apoptosis. Samples were acquired on
a CyANADP cytometer (Beckman Coulter) and analyzed by FlowJo soft-
ware (Tree Star Inc.).
Cell death in leukemia cell lines was evaluated after cell ﬁxation in
ethanol, treatment with 10 μg/ml RNase A (Sigma-Aldrich) and staining
with 100 μg/ml propidium iodide (PI) (Sigma-Aldrich).2.4. mRNA expression and sequencing
Total RNA was isolated using TRIzol reagent (Invitrogen) and
checked for quality by gel electrophoresis. One μg of total RNA was
reverse-transcribed using random hexamer primers and reagents of
Life Technologies.
Quantitative real-time PCR (qRT-PCR) were carried out using
Applied Biosystems® TaqMan® Universal PCR Master Mix (Life Tech-
nologies). TaqMan primers/probes for PARP1, PARP2, BRCA1, BRCA2
and GAPDH (for internal normalization) were from Integrated DNA
Technologies. Analysis was performed in triplicate on ABI-7900HT
(Applied Biosystems). The 2−ΔΔCt relative quantiﬁcation method was
used to calculate relative mRNA expression. A normal BM RNA was
used as a calibrator. Statistical analysis was performed using non-
parametric one-tailed Mann–Whitney test. Results were considered
signiﬁcant for p values ≤ 0.05.
NPM1mutA and FLT3-ITD gene status was investigated as previously
described [29] with minor changes. Brieﬂy, reverse-transcribed RNA
was screened by PCR-capillary electrophoresis methods and the PCR
setup was modiﬁed for Applied Biosystems 3130 platform.
The following primers were used: for FLT3 forward primer
ITD-F5=5′-tgtcgagcagtactctaaaca-3′, reverse primer ITD-R6=5′-
atcctagtaccttcccaaactc-3′; for NPM1 forward primer NM-F2=5′-
atcaattatgtgaagaattgcttac-3′, reverse primer NPM-Rev6=5′-
accatttccatgtctgagcacc-3′.
ITD-R6 andNPM-Rev6 primerswere labeledwith theﬂuorochromes
6-FAM and the FLT3 and NPM1 gene analysis was performed in two
different PCR reactions using AmpliTaq Gold DNA-polymerase (Life
Technologies). PCR conditions were adapted as follows: pre-
incubation at 95 °C for 7 min followed by 30 s at 94 °C, 30 s at 57 °C,
and 30 s at 72 °C for 35 cycles, and a ﬁnal elongation at 72 °C for
10 min. One μl of PCR product was mixed with deionized formamide
and ROX500 dye size standard (Life Technologies) according to the
manufacturer's instructions, heated to 95 °C for 5 min, and placed onTable 1
Clinical and biological characteristics of AML patients.
IC50 olaparib (μM) AML Age/sex WBC (×106/ml) % blasts (BM) K
82,4 AML-7 56/M 53 80 4
29,9 AML-17 59/M 7 40 N
17,9 AML-4 58/M 25 90 N
13,7 AML-12 50/M 57 72 4
13,6 AML-3 51/F 6 60 4
9,2 AML-6 35/M 58 90 4
4,5 AML-13 34/M 63 73 4
4,3 AML-9 23/M 102 90 N
3,5 AML-10 54/F 17 60 4
3,5 AML-15 58/M 26 40 4
3,3 AML-5 59/F 105 60 4
3,0 AML-1 41/F 28 80 4
2,8 AML-14 55/M 116 82 4
2,7 AML-2 56/F 94 80 4
2,6 AML-11 38/M 88 90 4
1,5 AML-16 40/M 5 21 4
0,7 AML-8 30/M 16 95 4
NA = Not Available.ice for at least 1min before electro-kinetic injection to the ABI 3130 cap-
illary electrophoresis instrument (Applied Biosystems).
2.5. Immunoblotting
Total proteins were extracted from AML cells collected before cul-
ture and treatment. Cells were lysed using a buffer containing 50 mM
Tris–HCl (pH 7.5), 5 mM EDTA, 5 mM EGTA, 150 mM NaCl, 1% Nonidet
P-40, 1mMNa orthovanadate, 20mMβ-glycerophosphate, 25mMNaF,
1 mMPMSF and protease inhibitor cocktail (Sigma-Aldrich). Protein al-
iquots were loaded onto Any KDtm or 7.5% Mini-Protean TGX polyacryl-
amide gels (Bio-Rad). After transferring to nitrocellulose membrane
total proteins were incubated with the following antibodies: anti-
PARP1 (M01-3G4, Abnova), anti-PARP2 (ab176330, Abcam), anti-
MRE11A (H-300, Santa Cruz), anti-MLH1 (G168-15, BD Pharmingen),
anti-MSH2 (Ab-1, Calbiochem), anti-MSH3 (52, BD Pharmingen), anti-
BRCA1 (D-9, Santa Cruz), anti-BRCA2 (9012, Cell Signaling Technology),
anti-RAD51 (14B4, Thermo), anti-γH2AX (JBW301,Millipore), anti-PAR
(4335, Trevigen) and anti-β-actin (4967, Cell Signaling Technology).
Horseradish peroxidase-conjugated IgG were used as secondary anti-
bodies. The autoradiograms were subjected to densitometric analysis
by ImageJ 1.45s software (Bio-Rad Laboratories). The results were nor-
malized against β-actin and used for statistical correlation analyses.
2.6. Immunoﬂuorescence of γH2AX foci
AML cells were cytocentrifuged (5–10 × 104 cells), ﬁxed with 4%
paraformaldehyde, permeabilized in 0.3% triton, blocked in 2% BSA
(Sigma-Aldrich) and immunostained with mouse anti-γH2AX. After
staining, cells were washed and incubated with goat anti-mouse IgG
Alexa Fluor 488 (Invitrogen). Nuclei were then stained with DAPI (4,6
diamidino-2-phenylindole) and mounted in Fluoromount (Sigma-
Aldrich). Analysis was performed using a Leica CTR 6000 ﬂuores-
cence microscope and LAS AF Lite software (Leica). Images were
taken at 40× magniﬁcation.
3. Results
3.1. AML blasts are sensitive to olaparib in vitro
Sensitivity to the PARPi-mediated cytotoxicity was evaluated by
trypan blue exclusion cell count (Fig. 1A–B). The requirement of cell
progression to S phase for the conversion of PARPi-induced SSB in DSB
prompted us to verify whether PARPi sensitivity of AML blasts was
inﬂuenced by the in vitro proliferation rate. Thus, AML samples werearyotype NPM1mutA FLT3-ITD Prognostic risk
6,XX,ins(10;11)(p12;q2313) Neg Neg Intermediate
A Pos Pos High
A Pos Neg Low
6,XY,t(5;21)(q32;q22)[8]/46,XY[9] Pos Pos High
6,XX,t(8;21) Neg Neg Low
6,XY,inv(16) Neg Neg Low
6,XY Pos Pos High
A [PCR positive for inv(16)] Neg Neg Low
6,XX Pos Pos High
7,XY,+8[2]/46,XY[28] Neg Neg Intermediate
6,XX Pos Neg Low
6,XX Pos Pos High
6,XY Pos Neg Low
6,XX,inv(16) Neg Neg Low
7,XY,+6[12]/46,XY[2] Pos Pos High
6,XY Neg Neg Intermediate
6,XY,del(11)(q23)[7]/46,XY[13] Neg Neg Intermediate
466 I. Faraoni et al. / Biochimica et Biophysica Acta 1852 (2015) 462–472divided in two groups including cycling (panel A) or non-proliferating
leukemic blasts (panel B). The doubling times of cycling blasts were
extremely variable ranging from 54 to 318 h. The most responsive
case (AML-8) (IC50 = 0.7 μM) was characterized by an extremely high
growth rate (Fig. 1A), whereas the olaparib resistant case AML-7
(IC50 = 82.4 μM) did not proliferate in vitro (Fig. 1B). However, 2 out
of 3 AMLs that did not proliferate in vitro at the assessed time points,
showed high responsiveness to olaparib (Fig. 1B). These ﬁndings sug-
gest that the antitumor effect of olaparib does not strictly depend onA
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Fig. 2. Lymphocytes from AML patients and normal hematopoietic cells have low sensitivity to
agnosiswere treatedwith increasing concentrations of olaparib. (A) Growth curves of proliferat
treatment (right panel). (B) Apoptosis following 7 days of exposure to 10 μM olaparib detected
ulations by side scatter and CD45. After separation and culture for 7 days surviving blasts excee
induced a decrease in the percentage of viable leukemic cells (lower cells) which is accompanied
resistant sample the percentage of the two populations remained constant after olaparib treatm
of olaparib treatment (right panel) of one BM (BM-1) and two CD34-enriched mobilized peripthe in vitro proliferative potential of leukemic blasts. Indeed, no statisti-
cally signiﬁcant correlation was observed between the proliferation in-
dexes of tested AMLs and olaparib IC50s. Overall, the results indicated
that a single treatment with PARPi induced a dose-dependent decrease
of cell survival in 13 out of 14 AML samples, with IC50s of sensitive AML
cases ranging from 0.7 to 17.9 μM(Fig. 1A–B). These values are below or
within the range of the plasma peak concentrations reached in patients
with solid tumors who were treated with 200–600 mg olaparib given
twice daily [22,27,30,31].AML IC50 ( M) 
AML-17 29.9
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2.5 10
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olaparib. Three primary proliferating AML samples with percentages of blasts ≤40% at di-
ing untreated primary AML cells (left panel) and surviving fractions after 7 days of olaparib
by FACS analysis after staining with Annexin V/PI. Viable cells were separated in two pop-
ded 75% in all untreated AML samples. In AML-15 and AML-16 sensitive samples olaparib
by an increase in the percentage of lymphocytes (upper cells). On the contrary, in AML-17
ent. (C) Growth curves of untreated controls (left panel) and surviving fractions after 7 days
heral blood samples (PB-1 and PB-2) obtained from healthy donors. NE = Not Evaluable.
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drug exposure, showed that olaparib concentrations ranging from 1.25
to 10 μM were able to induce apoptosis in sensitive AML blasts
(Fig. 1C). The PARPi induced apoptosis also in the two responsive leuke-
mia samples that did not proliferate in vitro (i.e., AML-9 and AML-11). A
representative experiment showing the dose-dependent increase of
pre-apoptotic and apoptotic cells mediated by olaparib in AML-5 cells
is shown in Fig. 1D.
Next, we analyzed whether a correlation existed between the
olaparib IC50 values at 7 days and some of the most important clinical
prognostic indexes of the AML blasts (i.e., age, white blood cell count,
karyotype, NPM1mutA and FLT3-ITD) (Table 1). However, no statistical-
ly signiﬁcant correlation was found between the sensitivity of leukemic
blasts and the above considered prognostic factors. AML-8 cells, which
resulted to be the most sensitive to the anti-proliferative and apoptotic
effects of olaparib, were characterized by a chromosome 11q23 deletion
(Table 1).
3.2. Lymphocytes from AML patients and normal hematopoietic cells have
low sensitivity to olaparib
In clinical trials olaparib monotherapy displayed a favorable toxicity
proﬁle as compared to most chemotherapeutic agents commonly used
for cancer treatment [22–24]. To investigate the effect of olaparib on
normal lymphocytes present in the BM of leukemia patients, 3 AML
samples, characterized by a low percentage of blasts at the time ofno
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Fig. 3.mRNA expression of PARP1, PARP2, BRCA1 and BRCA2 in normal hematopoietic cells an
tracted from BM of AML patients and healthy donors. Relative expression was obtained normal
are presented as themean of triplicate analysis. Statistical analysis was performed using the nodiagnosis (≤40%), were treated with olaparib. These AML samples
showed comparable growth rates (Fig. 2A, left panel), but different sen-
sitivity to olaparib, being AML-15 and AML-16 more responsive than
AML-17 cells (Fig. 2A, right panel). Flow cytometric analysis, performed
after 7 days of culture, indicated that in all samples the percentages of
blasts, characterized by low expression of CD45, markedly increased
due to the cell puriﬁcation procedures and the in vitro culture
(Fig. 2B). The higher level of apoptosis induced by olaparib in AML-15
and AML-16 samples is consistent with the results of cell proliferation
assay (Fig. 2A). Gate analysis of Annexin V and PI negative cells (viable
cells) indicated that in AML-15 and AML-16 sensitive samples the expo-
sure to 10 μM olaparib caused a decrease in the percentage of blasts
(CD45 low) and, consequently, an increase in the percentage of normal
lymphocytes (CD45 high) (Fig. 2B). These data suggest that olaparib
preferentially killed leukemia blasts and spared lymphocytes from the
same patient. By contrast, the PARPi minimally affected both cell popu-
lations in AML-17 cells that are characterized by an olaparib IC50 8.5-
fold and 20-fold higher than that of AML-15 and AML-16 cells,
respectively.
The inﬂuence of olaparib on normal hematopoietic cells, isolated
from one BM and from two CD34-enriched mobilized peripheral blood
samples, was also analyzed. Treatment with the PARPi did not affect
the survival of BM cells. Mobilized peripheral blood samples showed in-
stead a certain degree of sensitivity to olaparib. However, it should be
noted that olaparib IC50 values were higher than those obtained with
the majority of AML blasts (Fig. 2C vs Figs. 1 and 2A).no
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468 I. Faraoni et al. / Biochimica et Biophysica Acta 1852 (2015) 462–4723.3. mRNA expression of PARP1/2 and BRCA1/2 is altered in de novo AML
cells
It has been recently reported that the expression of PARP1 and
PARP2 is required for olaparib cytotoxic effects since PARP1−/− knock-
out B-lymphoblast avian cells, which are devoid of PARP2 expression,
are unresponsive to the PARPi [32]. In addition, BRCA1/2 homozygous
mutations or epigenetic down-regulation of their expression has been
widely demonstrated to result in HR-deﬁciency and responsiveness to
the synthetic lethality induced by PARPi monotherapy [8,9]. Based on
these observations we speculated that differences in the expression of
PARP1, PARP2, BRCA1 and BRCA2 between normal and leukemia cells
might account for the resistance of normal hematopoietic cells to
olaparib. Thus, we analyzed mRNA expression of these four genes in 9
normal and 25 AML BM samples (including the 17 AML samples tested
for chemosensitivity) by qRT-PCR. A higher expression of PARP2 was
observed in AML as compared to normal BM samples, whereas PARP1
mRNA levels in leukemic blasts were not signiﬁcantly different from
those present in normal cells (Fig. 3). However, it should be noted
that AML-7 and AML-17, regarded as the least sensitive AML, expressed
PARP1 transcript largely above the median range.
On the contrary, BRCA1 transcript was down-regulated in AML sam-
ples (Fig. 3), supporting a less effective HR repair that might account for
the sensitivity to olaparib.
3.4. AML cell lines are sensitive to olaparib: γH2AX and RAD51 as
biomarkers of olaparib sensitivity
In order to verify whether the high rate of response observed in pri-
mary AML blasts might be due to an unintended selection of sensitive
AML samples we analyzed 6 leukemia cell lines known to be unrespon-
sive to the PARPi Ku0058948 [21]. The olaparib IC50s of leukemia cell
lines at 7 dayswere comprised between 1.0 and 10.7 μM(Fig. 4). In par-
ticular, U937 cells were the least sensitive with an IC50 of about 11-fold
higher than that of NB4 cells. Overall, all the AML cell lines tested were
responsive to clinically relevant concentrations of olaparib.
In the search of a predictive marker of response to olaparib we eval-
uated byWestern blot analysis the expressionof a number of repair pro-
teins that might be involved in sensitivity to PARPi. For this purpose, we
initially tested basal PARP1, PARP2 protein expression and PARylated
proteins, as a measure of PARP activity, in the AML cell lines (Fig. 5A).
Both U937 and NB4 cells, although characterized by different olaparib
IC50s (i.e. 10.7 and 1.0 μM), expressed comparable low PARP1 and
PARylated proteins. Indeed, no statistically signiﬁcant correlation was
found between the results of densitometric analysis of PARP1, PARP2
and PAR immunoreactive bands and olaparib IC50s (Fig. 5A). In addition,
no correlation was also found between the expression of MRE11A and
the mismatch repair proteins MLH1, MSH2, MSH3 and drug sensitivity.
In particular, the HL-60R cell line, which overexpressesMSH3 as a result
of gene ampliﬁcation [33], responded to olaparib similarly to the HL-60
wild-type counterpart which expresses 15-fold lower levels of MSH3
(Fig. 5A).
With respect to proteins involved in DSB repair, in our experimental
conditions we did not observe detectable levels of BRCA1 and BRCA2 in
all the AML cell lines tested. Interestingly, RAD51 directly correlated
(Spearman's correlation 0.829; p = 0.021) and γH2AX inversely corre-
lated (Spearman's correlation −1.000; p b 0.0001) with the olaparib
IC50s. In particular, U937 cells showed undetectable basal levels of
γH2AX as compared to the olaparib hypersensitive NB4 cells (Fig. 5A).
These data support the role of the repair proteins RAD51 and γH2AX
as potential markers of olaparib sensitivity in AML cell lines.
Cell death and γH2AX foci formation were then analyzed in U937,
HL60 and NB4 cells 24 h after treatment with 1.25 and 5 μMof olaparib.
The results indicated that in the AML cell lines the toxic effects caused
by olaparib were evident as early as 24 h after drug exposure, especially
in the most sensitive cells (i.e. HL-60 and NB4; Fig. 5B). In the case ofU937 cells, although the percentage of dead cells slightly increased at
later time points (i.e., 72 and 120 h), it remained always lower than in
HL-60 and NB4 cells (data not shown). Moreover, the PARPi caused a
dose-dependent increase in the number γH2AX positive cells which
correlated with sensitivity to olaparib (Fig. 5C). Consistent with the re-
sults of immunoblot analysis the number of γH2AX foci in untreated
NB4 and HL-60 cells was higher than in U937 cells.3.5. In primary AML PARP1 over-expression and BRCA1 proﬁciency indicate
resistance to olaparib, whereas formation of γH2AX foci indicates
sensitivity
Based on the results obtained in the AML cell lines we analyzed by
Western blot the expression of PARP1, PARP2, RAD51, γH2AX, BRCA1,
BRCA2 and PARylated proteins in the AML blasts isolated from patients
(Fig. 6A). PARP1 protein expression signiﬁcantly correlated with PAR
levels (Spearman's correlation 0.575; p = 0.02) and PARP1 mRNA
(Spearman's correlation 0.746; p = 0.002) (Fig. 6A–B). No statistically
signiﬁcant correlation was found between the results of densitometric
analysis of PARP1, PARP2 and PAR immunoreactive bands and olaparib
IC50s. Nevertheless, AML-7 cells with the highest olaparib IC50 also
showed the highest amount of PARP1 protein and mRNA levels
(Fig. 6B and Fig. 3). Differently from the results obtained in AML cell
lines, no correlation was observed between olaparib IC50s in primary
AML blasts and basal RAD51 or γH2AX protein expression analyzed be-
fore culture.
In keeping with the ﬁndings obtained in the AML cell lines, BRCA2
protein was hardly detectable in all AML primary samples, whereas
BRCA1 protein was only detected in the olaparib resistant AML-7
469I. Faraoni et al. / Biochimica et Biophysica Acta 1852 (2015) 462–472sample. Thus, the concomitant condition of high PARP1 expression and
the presence of BRCA1 in AML-7 might account for its resistance to
olaparib.
AML samples were then examined for their ability to form γH2AX
foci in response to treatment with olaparib. For immunoﬂuorescence
analysis we collected 8 AML samples 72 h after drug treatment
(Fig. 6C). An inverse correlation was found between the olaparib IC50s-
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In the present studywe show that the PARPi olaparib as single agent
exerts antiproliferative and apoptotic effects in AML blasts at clinically
achievable concentrations. By contrast, normal lymphocytes or hemato-
poietic cells from healthy donors showed low sensitivity to olaparib re-
gardless of the sensitivity/resistance proﬁle of matched leukemic blasts.
The exposure to a single dose of olaparib was able to exert cell killing in
a high percentage (88%) of primary AML samples. Only in 2 out 17 cases
the olaparib IC50 was≥25 μM, i.e. higher than themaximum concentra-
tion achievable in patients with solid tumors who were treated with
200–600 mg olaparib twice daily.
At present, the efﬁcacy of PARPi as monotherapy has been mostly
conﬁned to patientswith BRCA1/2mutations and related to synthetic le-
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were probed with γH2AX (green stain) and DAPI (blue).PARP1 activity. However, mutations in BRCA1/2 genes are not common
in acute leukemia [34]. Nevertheless, a decreased expression of BRCA1/2
proteins causing impairment of HR may also derive from mechanisms
different from gene mutations [9,35,36]. In addition, olaparib has been
shown to induce objective responses in patients with ovarian cancer
also in the absence of BRCA mutations [25].
Our results show that AML blasts express lower levels of BRCA1/2
transcripts as compared to BMsamples derived fromhealthy donors. In-
deed, a reduced BRCA1 expression due to promoter hypermethylation
was reported in therapy-related AML cells [37]. Moreover, although
BRCA transcripts were measurable in all samples, the corresponding
proteins were barely detectable or not present in the AML cell lines
and patient blasts. Thus, alterations in post-transcriptional regulatory
mechanisms might inﬂuence the expression of BRCA proteins in AML.
Moskwa et al. [38] reported that over-expression of miR-182 in the0
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BRCA1 and confers sensitivity to two different PARPi. Since the only re-
sistant AML sample (i.e., AML-7) that we could analyze byWestern blot
showed the highest expression of BRCA1 and all the remaining samples
presented undetectable or low levels of BRCA1 and BRCA2, we can rea-
sonably assume that the low expression of these proteins contributes to
the sensitivity of AML to olaparib.
It should be observed that the drug concentrations used in our study
are higher than those required by olaparib to inhibit the catalytic activ-
ity of puriﬁed PARP1 and PARP2 proteins (i.e. IC50: PARP1 = 0.005 μM,
PARP2= 0.001 μM). In previous works, in vitro sensitivity of certain tu-
mors to nanomolar concentrations of olaparib was linked to inhibition
of PARP catalytic activity [15,17]. However, higher concentrations of
the PARPi may cause cell death by additional mechanisms. For instance,
in the work by Hegan et al. [39] several PARPi at μM concentrations
down-regulated BRCA1 and RAD51 expression increasing the occupan-
cy of their promoters by the repressive E2F4/p130 complexes. Recently,
Nowsheen et al. [40] observed that concentrations of veliparib and
olaparib ranging from 2.5 to 10 μM inhibited the HER2/NF-kB signaling
rendering HER2-positive breast cancers sensitive to the PARPi. More-
over,Murai et al. [32,41] reported a cytotoxicmechanismbased on trap-
ping of PARP1/2 on DNA complexes which varied in extent among the
different PARPi and was independent from their inhibitory effect on
PARP catalytic activity. Additional mechanisms of olaparib that have
been recently reported involve up-regulation of death receptors such
as FAS and DR5 leading to sensitization of tumor cells to death receptor
ligands [42]. Therefore, it is conceivable that the cytotoxicity exerted by
olaparib in AML cells also depends on inhibition of other PARP functions
in addition to the proven block of PARylation and synthetic lethality.
Since PARP1 and PARP2 are the primary targets of PARPi we also in-
vestigated whether a relationship existed between their levels and the
response to olaparib. No statistically signiﬁcant correlation was found
between olaparib IC50s and PARP1, PARP2 mRNA or protein expression.
These data are in agreement with our recent ﬁndings on glioblastoma
stem cells using a different PARPi [43]. However, the two highly resis-
tant cases AML-17 and AML-7 showed the highest levels of PARP1 ex-
pression. In our experimental conditions, a threshold of PARP1 mRNA
relative expression set at 10 (the 2−ΔΔCt value) may be considered to
identify patients who may not beneﬁt from treatment with olaparib.
To the best of our knowledge, the up-regulation of PARP1 was reported
in some solid tumors [44,45] but, no information is still available from
clinical trials on the relationship between basal PARP1 expression in pri-
mary tumors and resistance to PARPi.
Primary blasts from AML-8 showing high sensitivity to olaparib
(IC50 = 0.7 μM) had a deletion at chromosome 11q23. The region 11q
comprises several genes known to be involved in the response to DSB,
including MRE11A, ATM and H2AFX alleles. Our ﬁndings are in agree-
ment with a recent report showing that lymphoid tumors with 11q de-
letion are highly responsive to olaparib [15]. Moreover, Gaymes et al.
[18] reported mutations in ATM, as well as inMRE11A, in cell lines char-
acterized bymicrosatellite instability that were responsive to PARPi, in-
cluding the hypersensitive NB4 cells.
Cancer treatment might be improved if information on the patient
individual response to a drug is available at diagnosis or early in the
course of treatment. The use of γH2AX as a pharmacodynamic response
to a DNA cross-linking agent has been recently adopted in a clinical trial
setting [46,47]. In our study we observed a strong correlation between
olaparib IC50s and basal γH2AX protein expression in AML cell lines an-
alyzed by immunoblot, but not in primary AMLswhen tested at baseline
before culture. On the other hand, a signiﬁcant correlation was found
between the sensitivity to olaparib and the number of basal γH2AX
foci in cultured AML blasts (Figs. 5C and 6C). It can be hypothesized
that the pattern of γH2AX expression in cycling blasts more likely re-
ﬂects the situation of leukemia cells in patients, since just after their iso-
lation from BM specimens blasts are typically arrested at G1/G0 phase.
An abnormal ability to repair the DNA damage caused by endogenousinsults might cause an increase of basal γH2AX foci in proliferating
AML blasts enhancing the sensitivity to PARPi. Indeed, elevated basal
γH2AX levels, which may result in dysregulation of DSB response,
have been recently reported in some therapy-related AML [48]. More-
over, we found an increased number of γH2AX foci in sensitive AML
blasts after a single treatmentwith olaparib, as a result of the DNAdam-
age caused by the drug.
In conclusion, we show here that a single treatment with olaparib
caused cell killing in themajority of primary AML blats tested at concen-
trations achievable in cancer patients, likely due to low expression of
BRCA proteins. Moreover, PARP1 mRNA over-expression and γH2AX
foci appear to be promising candidate biomarkers to predict resistance
or response. The favorable side effects proﬁle and the good oral bioavail-
ability of olaparib render this drug an attractive therapeutic option
as monotherapy for AML patients not suitable for conventional
chemotherapy.
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